Federal Register #2026-21985

AHRQ seeks extension of clearance for questionnaire and data-collection research

AHRQ is seeking public comments on continuing its generic clearance for research that tests and improves questionnaires and data-collection methods. - Government buyer: Department of Health and Human Services (HHS), Agency for Healthcare Research and Quality (AHRQ); no specific office is identified. - Opportunity type: Information-collection notice, not a request to buy products or services. AHRQ seeks a three-year extension of OMB clearance 0935-0124, without changes. - Research activities: Voluntary mail/email, telephone, and web surveys; focus groups; in-person interviews; automated data collection; and cognitive testing. The work supports improving existing methods and developing or revising data collections and related toolkits. - Estimated participation and burden: 4,600 respondents and 2,967 annual burden hours; estimated annual respondent cost is $310,111. These are research burden estimates, not a contract value. - Important limitations: The research is not intended to support public data release or policy formation. No vendors, OEMs, product quantities, or purchasable items are identified. The document also begins an unrelated FDA notice mentioning Bixlenvo (bictegravir and lenacapavir), with no procurement details.

Description

The Agency for Healthcare Research and Quality (AHRQ) plans to request that the Office of Management and Budget approve a three-year extension, without changes, of its information collection clearance for questionnaire and data collection testing, evaluation, and research (OMB #0935-0124). The work supports testing and developing survey instruments, toolkits, and data collection and estimation procedures, as well as revising existing procedures. The research activities are voluntary and are not intended for public data release or policy formation. Comments are due December 28, 2026.

View original listing